Novartis Targets 5% Annual Sales Growth Through 2031 Despite Patent Expirations

Novartis logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Novartis expects 5% annual sales growth from 2026 through 2031, with average mid-single-digit growth into the mid-2030s, despite patent expirations. The forecast assumes loss of exclusivity for Cosentyx and KESIMPTA and a Kisqali expiration-related impact beginning in mid-2031.
  • The company aims to reach a core operating margin of 40% by 2029 and maintain at least that level thereafter. Growth and productivity gains, including anticipated AI efficiencies, are expected to offset generic competition and pricing pressures.
  • Novartis raised peak-sales targets for several newer medicines, including KESIMPTA to $8 billion and LEQVIO to $5 billion, and expects 35 potential submission-enabling pipeline readouts. Executives also highlighted clinical trial risks and plans to expand U.S. manufacturing, with local supply expected from 2029.
  • Interested in Novartis? Here are five stocks we like better.

Novartis NYSE: NVS expects annual sales growth of 5% from 2026 through 2031 and average mid-single-digit growth into the mid-2030s, as the drugmaker looks to offset patent expirations with newer medicines and its development pipeline.

CEO Vas Narasimhan outlined the forecast at the company’s Meet Novartis Management event, where executives also discussed pricing pressures, clinical trial risks, artificial intelligence and plans to expand U.S. manufacturing.

The company maintained its existing outlook for 5% to 6% sales growth from 2025 through 2030. It also expects to reach a 40% core operating margin by 2029 and sustain a margin of at least 40% thereafter, Chief Financial Officer Mukul Mehta said.

Growth Forecast Accounts for Patent Expirations

Narasimhan said the 2031 forecast assumes loss of exclusivity for Cosentyx and KESIMPTA on their respective expiration dates and for Kisqali on its settlement date. Any extension beyond those assumptions would be an upside to the forecast, he said.

The company expects the U.S. loss of exclusivity for breast cancer medicine Kisqali to have an impact from the middle of 2031. Narasimhan said growth rates could slow in years affected by major expirations, while emphasizing that the mid-single-digit outlook for 2031 to 2035 is an average rather than a promise for every year.

Novartis expects Cosentyx sales to peak in 2027 before U.S. pricing changes take effect in 2028. Kisqali will also face a price-related decline in 2028, but the company expects the medicine to return to growth and reach its $10 billion peak-sales target around 2030, Narasimhan said.

For 2026, Novartis expects low-single-digit sales growth and core operating income growth ranging from broadly in line with the prior year to low single digits, despite expirations affecting Entresto, Tasigna and Promacta.

Higher Sales Targets and Pipeline Plans

Novartis raised its peak-sales outlook for multiple medicines, including KESIMPTA to $8 billion from $6 billion and LEQVIO to $5 billion. It also lifted its outlook for RHAPSIDO to more than $8 billion following a positive relapsing multiple sclerosis readout.

During the question-and-answer session, Jefferies analyst Michael Leuchten asked how recent high-profile trial failures affected the company’s approach to assessing pipeline risk. Narasimhan said Novartis models each asset individually, taking account of its data and therapeutic area. Ronny Gal, head of strategy and growth, said the company expects material attrition and needs a sufficiently broad portfolio.

UBS analyst Matthew Weston asked about patent-life assumptions, while TD Cowen analyst Steve Scala questioned the decision to raise the LEQVIO forecast ahead of the ORION-4 trial readout. Narasimhan cited strong commercial performance and said Novartis had initiated another study, V2P, to help mitigate risk around ORION-4.

Narasimhan said the company expects 35 potential submission-enabling readouts across its pipeline. Among the programs discussed were:

  • Abelacimab: Novartis expects a readout from the LILAC study by mid-2027 and a submission in 2027. Narasimhan said the trial passed an interim analysis without a change to its sample size.
  • GHZ339: The company disclosed the atopic dermatitis program and expects to begin a Phase III study in 2027. Narasimhan said a Phase IIb study met its primary endpoint at the 600 mg dose.
  • Ianalumab: Novartis continues to expect a Sjögren’s approval before year-end. Narasimhan said discussions with the Food and Drug Administration included how to characterize patients who benefit most.
  • Actinium PSMA: Novartis expects two Phase III readouts in 2028 for the prostate cancer program.

Margin, AI and Manufacturing

Mehta said margin pressures over the next several years include European generic competition for Entresto and U.S. pricing effects on Cosentyx and Kisqali. Sales growth and productivity measures are expected to offset those pressures, he said.

The margin outlook already includes anticipated productivity gains from AI through 2029, Mehta said. Narasimhan added that a faster AI transformation could provide upside, although he described improving the probability of clinical success as a longer-term challenge.

On manufacturing, Head of Operations Steffen Lang said Novartis is building out its U.S. footprint to supply branded and key products locally from 2029. Narasimhan said producing medicines in the U.S. for that market would help insulate the company from future political changes, while acknowledging that U.S. production carries a higher cost of goods.

About Novartis (NYSE:NVS)

Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company's medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Novartis Right Now?

Before you consider Novartis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.

While Novartis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines